EMA Authorised: Otezla (apremilast) — Amgen Europe B.V.

View source ↗

Summary

The European Medicines Agency authorised Otezla (apremilast) for Behçet syndrome, in addition to its established uses in psoriatic arthritis and psoriasis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Behçet Syndrome
• Psoriasis
• Psoriatic Arthritis

Drugs mentioned

• OTEZLA (apremilast)

Snippet

Status: Authorised. Therapeutic area: Arthritis, Psoriatic;Psoriasis;Behcet Syndrome. MAH: Amgen Europe B.V.. Decision date: 13/01/2026